MiNK Therapeutics reports favorable lung immune data for cell therapy candidate
MiNK Therapeutics (NASDAQ:INKT) disclosed new clinical and translational data demonstrating that its off-the-shelf allogeneic cell therapy, agenT-797, successfully induced localized tissue repair and pathogen clearance when administered to a critically ill pulmonary patient.























